8-K: Profound Medical's TULSA Procedure Outperforms Robotic RP

Profound Medical's CAPTAIN trial demonstrates the TULSA Procedure's superior safety and functional outcomes compared to robotic radical prostatectomy for prostate cancer.

Summary

• The CAPTAIN trial met its primary safety endpoint, showing statistical superiority of the TULSA Procedure over robotic radical prostatectomy (RP) for men with localized prostate cancer.
• The TULSA Procedure preserved both erectile function and urinary continence in 50% of patients at 6 months, compared to 24% after RP (p<0.05, risk ratio 2.1).
• Urinary continence was superior after TULSA, with 84% preserving pad-free continence at 6 months versus 49% after RP.
• Patient-reported erectile function was preserved in 56% of men at 6 months after TULSA compared to 47% after RP.
• TULSA demonstrated improved perioperative measures, including zero blood loss (vs. 150 mL for RP), no overnight hospital stay (vs. 1.1 days for RP), reduced pain, and faster return to paid employment (10 days vs. 19 days for RP).
• Significantly fewer patients incurred a complication requiring hospitalization within 90 days after TULSA (0.7%) compared to RP (6.3%).
• Secondary oncologic outcomes for the TULSA Procedure, including histology and imaging, are pending 12-month biopsy and MRI results, expected later this year.
• The RP arm showed 33% positive surgical margins and 35% upstaged on surgical pathology, consistent with nerve-sparing techniques prioritizing functional preservation.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive announcement, demonstrating the TULSA Procedure's significant clinical advantages over the current standard of care in key quality-of-life metrics and safety, which could drive substantial market adoption.

Positives

• The TULSA Procedure achieved statistical superiority on the primary composite safety endpoint, preserving both erectile function and urinary continence in 50% of patients at 6 months, more than double the rate of RP (24%).
• Significantly better preservation of urinary continence (84% pad-free vs. 49% for RP) and erectile function (56% vs. 47% for RP) at 6 months.
• Superior perioperative outcomes included zero blood loss, no overnight hospital stay, reduced pain, and faster return to work (10 days vs. 19 days for RP).
• A lower rate of serious complications requiring hospitalization (0.7% for TULSA vs. 6.3% for RP) within 90 days.
• The CAPTAIN trial successfully recruited 211 patients, exceeding the initial target of 201, across 23 sites.

Negatives

• Secondary oncologic outcomes for the TULSA Procedure arm are not yet available and are pending 12-month biopsy and MRI results, which are expected later this year.
• The robotic radical prostatectomy (RP) outcomes in the trial were achieved by high-volume robotic surgeons with extensive experience and the use of nerve-sparing techniques in 95% of cases, indicating TULSA's superiority was against an optimized surgical benchmark.

Risks

• Risks regarding the medical device industry, regulatory approvals, and reimbursement.
• Economic factors and the equity markets generally could impact the company.
• Risks associated with growth and competition in the medical device sector.
• Forward-looking events and circumstances may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties.

Future Outlook

The company expects to report secondary oncologic outcomes for the TULSA Procedure arm later this year, which will provide a window into the 3-year primary oncologic endpoint. The goal of the CAPTAIN trial is to demonstrate TULSA's non-inferiority to RP in efficacy while showing superior quality of life outcomes, potentially facilitating its inclusion in standard of care guidelines.

Management Comments

• Dr. Laurence Klotz commented, "CAPTAIN is a first-of-its-kind study, successfully recruiting patients into a head-to-head comparison of the TULSA Procedure and robotic RP for both safety and oncologic control. The study tests whether the TULSA Procedure is superior to RP for functional outcomes and not inferior to RP for oncologic control. Establishing these outcomes would facilitate moving the TULSA Procedure into the standard of care. We have reached a foundational milestone by proving superior safety. At 6 months, patients treated with TULSA-PRO were more than twice as likely to preserve both pad-free continence and erections sufficient for intercourse compared to surgery, delivering functional outcomes that track the established body of evidence for the TULSA Procedure. The TULSA Procedure also proved a less invasive experience marked by zero blood loss and no overnight stay, faster recovery to baseline, day-to-day activities and return to work, and significantly fewer, serious complications. Secondary oncologic endpoints available later this year for the TULSA Procedure arm will serve as a window into the 3-year primary oncologic endpoint."
• Arun Menawat, Profound's CEO and Chairman, stated, "CAPTAIN now positions us to demonstrate with statistical rigor the TULSA Procedures superior quality of life profile while delivering the whole-gland treatment efficacy of robotic RP. We look forward to announcing additional clinical outcomes from this unique, potentially paradigm-changing study when they become available later this year."

Industry Context

StockSavvy.ai notes that the successful CAPTAIN trial results position Profound Medical's TULSA Procedure as a strong contender against robotic radical prostatectomy, the current gold standard for localized prostate cancer treatment. The demonstrated superiority in functional outcomes and safety, particularly against optimized surgical conditions, could significantly disrupt the urology market by offering a less invasive option with better quality of life for patients.

Comparison to Industry Standards

• The TULSA Procedure demonstrated superior preservation of erectile function and urinary continence (50% vs. 24% for RP at 6 months), significantly outperforming robotic radical prostatectomy (RP).
• TULSA achieved 84% pad-free continence at 6 months, compared to only 49% for RP, and 56% erectile function preservation compared to 47% for RP. These TULSA outcomes are consistent with its single-arm TACT pivotal FDA registration study (86% continence, 59% erectile function).
• RP outcomes in the trial, despite being performed by high-volume robotic surgeons using nerve-sparing techniques in 95% of cases, still showed higher blood loss (150 mL vs. zero), longer hospital stays (1.1 days vs. no overnight stay), and higher serious complication rates (6.3% vs. 0.7%) compared to TULSA.
• The trial directly compares TULSA-PRO to robotic RP, which is a widely adopted surgical approach for prostate cancer, often performed using systems like Intuitive Surgical's da Vinci. The results suggest TULSA offers a compelling alternative with improved patient quality of life metrics.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results, potentially leading to increased market adoption, revenue growth, and share price appreciation.
• Patients: Significant positive impact through a less invasive treatment option for prostate cancer with superior preservation of quality-of-life outcomes (erectile function and urinary continence), faster recovery, and fewer complications compared to traditional surgery.
• Healthcare Providers/Urologists: Provides a new, clinically superior tool for treating localized prostate cancer, potentially expanding treatment options and improving patient care.
• Competitors: Potential negative impact on companies offering robotic radical prostatectomy solutions if TULSA gains significant market share.

Next Steps

• Announce additional clinical outcomes, specifically secondary oncologic endpoints (histology and imaging from 12-month biopsy and MRI) for the TULSA Procedure arm, later this year.
• Advance the TULSA Procedure toward potential inclusion in prostate cancer treatment guidelines.
• Host an investor webinar today (March 13, 2026) at 11:30 a.m. EDT to review data and discuss commercial implications.
• Continue to monitor the 3-year primary oncologic endpoint for the CAPTAIN trial.

Key Dates

Recommendation

The CAPTAIN trial results represent a significant clinical breakthrough, demonstrating the TULSA Procedure's superior safety and functional outcomes compared to robotic radical prostatectomy, even against optimized surgical conditions. This Level 1 evidence is crucial for driving adoption and potentially establishing TULSA as a new standard of care. While oncologic efficacy data is still pending, the strong safety and quality-of-life profile, coupled with a less invasive experience, positions Profound Medical for substantial market penetration and growth, making it a strong buy for long-term investors.

Keywords

Profound Medical, TULSA Procedure, Prostate Cancer, Robotic Radical Prostatectomy, MRI-guided therapy, CAPTAIN trial, Medical Device, Urology, Erectile Dysfunction, Urinary Continence, Oncologic Control, Sonalleve, BPH, Bone Metastases